59170-23-9

Basic information

• Product Name: Bevantolol
• Synonyms: Bevantolol;2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-methylphenoxy)-;DL-Bevantolol;NSC 132348;1-(3,4-Dimethoxyphenethylamino)-3-(3-methylphenoxy)-2-propanol;1-[(3,4-Dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol;1-((3,4-DiMethoxyphenethyl)aMino)-3-(M-tolyloxy)propan-2-ol
• CAS NO: 59170-23-9
• Molecular Formula: C₂₀H₂₇NO₄
• Molecular Weight: 345.436
• Mol File: 59170-23-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 518.3°C at 760 mmHg
• Flash Point: 267.3°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 1.44E-11mmHg at 25°C
• Refractive Index: 1.55
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Bevantolol(CAS DataBase Reference)
• NIST Chemistry Reference: Bevantolol(59170-23-9)
• EPA Substance Registry System: Bevantolol(59170-23-9)

Safety Data

• Hazardous Substances Data: 59170-23-9(Hazardous Substances Data)

Usage

Originator

Bevantolol hydrochloride,Parke, Davis (Pfizer)

Enzyme inhibitor

This antihypertensive agent (FW = 345.43 g/mol; CAS 59170-23-9), also known by the code name NC-1400 and systematically as (RS)-[2-(3,4- dimethoxyphenyl)ethyl]-[2-hydroxy-3-(3-methylphenoxy)propyl]amine, is a dual-action b-blocker and calcium ion channel blocker. Bevantolol is a selective b1-adrenoceptor blocker with some blocking activity of a1- adrenoceptors.

InChI:InChI=1/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3

Upstream product

• 2186-25-6 m-tolyl glycidyl ether 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 42865-04-3 1-chloro-3-(3-methylphenoxy)-2-propanol 
• 108-39-4 3-methyl-phenol 

Downstream Products

• 175157-17-2 1-[[2-(3,4-Dimethoxyphenyl)-ethyl]-(4-fluorobenzyl)amino]-3-m-tolyloxy-propan-2-ol, oxalate 

Relevant articles and documents

DIMETHOXYPHENYL INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2

Described are dimethoxyphenyl inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Substituted phenoxyhydroxypropylamines as central nervous system agents.

-